USA flag logo/image

An Official Website of the United States Government

A Transporter-Based Predictive ADME Platform

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96532
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
RR031474
Solicitation Year:
N/A
Solicitation Topic Code:
NCRR
Solicitation Number:
N/A
Small Business Information
OPTIVIA BIOTECHNOLOGY, INC.
115 CONSTITUTION DR, STE 7 MENLO PARK, CA 94025-3712
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: A Transporter-Based Predictive ADME Platform
Agency: HHS
Contract: 1R43RR031474-01
Award Amount: $439,346.00
 

Abstract:

DESCRIPTION (provided by applicant): Desirable drug ADME (Absorption, Disposition, Metabolism and Elimination) properties are key determinants of a drug's to safety and efficacy. Unfortunately, poor ADME and Toxicity attributes have caused more drug failur es than any other factors. There is a pressing need for better in vitro predictive ADME tools to augment the decade-old animal studies which do not always predict clinical results in the human. The overall goal of this project is to ascertain whether in vi vo drug ADME properties could be explained and predicted based on drugs' in vitro interactions with transporter proteins, which have been demonstrated to play significant roles in every aspect of drug ADME, along with metabolic enzyme interaction and other drug physicochemical properties. The initial Phase I work will start with examining the roles of major liver transporters on hepatic disposition of drugs, through testing a panel of drugs against these transporters; novel in vitro models will be created f or studying the effects of transporters-CYP interplay on hepatic drug metabolism; finally, correlations between in vitro data and clinical disposition and metabolism information will be established. Future study would extend the scope to other major tissue s/organs with aims to explain and predict drug ADME properties and drug-drug interactions (DDI) based on in vitro transporter studies and other drug physicochemical properties. PUBLIC HEALTH RELEVANCE: Success of this project will benefit public hea lth by facilitating discovery and development of drugs for treating various formidable diseases, particularly CNS diseases and cancer, through enhancing drug efficacy by increasing targeted drug delivery to diseased tissues, and through improving drug safe ty by reducing adverse drug effects due to unwanted tissue distribution and drug-drug interactions.

Principal Investigator:

Dallas Bednarczyk
DBEDNARCZYK@OPTIVIABIO.COM

Business Contact:

Yong Huang
yhuang@optiviabio.com
Small Business Information at Submission:

OPTIVIA BIOTECHNOLOGY, INC.
OPTIVIA BIOTECHNOLOGY, INC. 115 CONSTITUTION DR, STE 7 MENLO PARK, CA 94025

EIN/Tax ID: 126014876
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No